Unknown

Dataset Information

0

IL-33 Is a Cell-Intrinsic Regulator of Fitness during Early B Cell Development.


ABSTRACT: IL-33 is an IL-1 family member protein that is a potent driver of inflammatory responses in both allergic and nonallergic disease. This proinflammatory effect is mediated primarily by extracellular release of IL-33 from stromal cells and binding of the C-terminal domain of IL-33 to its receptor ST2 on targets such as CD4+ Th2 cells, ILC2, and mast cells. Notably, IL-33 has a distinct N-terminal domain that mediates nuclear localization and chromatin binding. However, a defined in vivo cell-intrinsic role for IL-33 has not been established. We identified IL-33 expression in the nucleus of progenitor B (pro-B) and large precursor B cells in the bone marrow, an expression pattern unique to B cells among developing lymphocytes. The IL-33 receptor ST2 was not expressed within the developing B cell lineage at either the transcript or protein level. RNA sequencing analysis of wild-type and IL-33-deficient pro-B and large precursor B cells revealed a unique, IL-33-dependent transcriptional profile wherein IL-33 deficiency led to an increase in E2F targets, cell cycle genes, and DNA replication and a decrease in the p53 pathway. Using mixed bone marrow chimeric mice, we demonstrated that IL-33 deficiency resulted in an increased frequency of developing B cells via a cell-intrinsic mechanism starting at the pro-B cell stage paralleling IL-33 expression. Finally, IL-33 was detectable during early B cell development in humans and IL33 mRNA expression was decreased in B cell chronic lymphocytic leukemia samples compared with healthy controls. Collectively, these data establish a cell-intrinsic, ST2-independent role for IL-33 in early B cell development.

SUBMITTER: Stier MT 

PROVIDER: S-EPMC6736727 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


IL-33 is an IL-1 family member protein that is a potent driver of inflammatory responses in both allergic and nonallergic disease. This proinflammatory effect is mediated primarily by extracellular release of IL-33 from stromal cells and binding of the C-terminal domain of IL-33 to its receptor ST2 on targets such as CD4<sup>+</sup> Th2 cells, ILC2, and mast cells. Notably, IL-33 has a distinct N-terminal domain that mediates nuclear localization and chromatin binding. However, a defined in vivo  ...[more]

Similar Datasets

| S-EPMC7030950 | biostudies-literature
| S-EPMC6990979 | biostudies-literature
| S-EPMC5704190 | biostudies-literature
| S-EPMC5932021 | biostudies-literature
| S-EPMC10480426 | biostudies-literature
| S-EPMC4432012 | biostudies-literature
| S-EPMC3734634 | biostudies-literature
| S-EPMC5549601 | biostudies-literature
| S-EPMC5643372 | biostudies-literature
| S-EPMC4449115 | biostudies-literature